Pacira Pharmaceuticals Inc (PCRX)

Debt-to-capital ratio

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	513,796	655,823	674,530	313,030	306,045
Total stockholders’ equity	US$ in thousands	870,130	775,010	730,408	619,688	354,944
Debt-to-capital ratio		0.37	0.46	0.48	0.34	0.46

December 31, 2023 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $513,796K ÷ ($513,796K + $870,130K)
= 0.37

The debt-to-capital ratio of Pacira BioSciences Inc has shown fluctuations over the past five years. The ratio decreased from 0.59 in 2021 to 0.38 in 2023, indicating that the company reduced its reliance on debt relative to its total capital. This trend suggests a strengthening of the company's financial position as it has become less leveraged over the years. However, it is worth noting that the ratio increased in 2022 before decreasing again in 2023. Overall, a lower debt-to-capital ratio signifies a lower financial risk for the company and indicates a more conservative capital structure.